Marker Therapeutics (MRKR) Depreciation & Amortization (CF) (2019 - 2023)
Marker Therapeutics (MRKR) posted quarterly Depreciation & Amortization (CF) of $818216.0 for Q1 2023, up 41.97% year-over-year from $576331.0 in Q1 2022, and up 0.63% quarter-over-quarter from $813110.0 in Q4 2022.
Marker Therapeutics (MRKR) Depreciation & Amortization (CF) (2019 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $818216.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Depreciation & Amortization (CF) rose 41.97% year-over-year to $818216.0; the TTM figure through Dec 2023 stood at $818216.0 (down 70.66% YoY), while the FY2022 annual figure was $2.8 million, up 29.79% from the prior year.
- Depreciation & Amortization (CF) improved to $818216.0 in Q1 2023 per MRKR's latest filing, from $813110.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $819883.0 in Q3 2022 and bottomed at $10514.0 in Q1 2019.
- Historically, Depreciation & Amortization (CF) has averaged $373357.0 across 5 years, with a median of $502743.0 in 2021.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 1325.61% — and 2022, when it advanced 9.35%.
- Marker Therapeutics' Depreciation & Amortization (CF) stood at $34215.0 in 2019, then soared by 522.29% to $212916.0 in 2020, then soared by 165.12% to $564488.0 in 2021, then soared by 44.04% to $813110.0 in 2022, then advanced by 0.63% to $818216.0 in 2023.
- Business Quant data shows MRKR's Depreciation & Amortization (CF) at $818216.0 in Q1 2023, $813110.0 in Q4 2022, and $819883.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 818,216.00 |
| Mar 31, 2023 | 818,216.00 |
| Dec 31, 2022 | 813,110.00 |
| Dec 31, 2022 | 813,110.00 |
| Sep 30, 2022 | 819,883.00 |
| Sep 30, 2022 | 819,883.00 |
| Jun 30, 2022 | 579,782.00 |
| Jun 30, 2022 | 579,782.00 |
| Mar 31, 2022 | 576,331.00 |
| Mar 31, 2022 | 576,331.00 |
| Dec 31, 2021 | 564,488.00 |
| Dec 31, 2021 | 564,488.00 |
| Sep 30, 2021 | 551,524.00 |
| Sep 30, 2021 | 551,524.00 |
| Jun 30, 2021 | 530,228.00 |
| Jun 30, 2021 | 530,228.00 |
| Mar 31, 2021 | 502,743.00 |
| Mar 31, 2021 | 502,743.00 |
| Dec 31, 2020 | 212,916.00 |
| Dec 31, 2020 | 212,916.00 |